<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04695041</url>
  </required_header>
  <id_info>
    <org_study_id>PBI-4050-CT-9-20</org_study_id>
    <nct_id>NCT04695041</nct_id>
  </id_info>
  <brief_title>A Healthy Volunteer Study of PBI-4050</brief_title>
  <official_title>A Phase 1, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of PBI-4050 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liminal BioSciences Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Liminal BioSciences Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the study drug PBI-4050 to determine the safety,&#xD;
      tolerability and concentration profile in the blood when the drug is given to healthy&#xD;
      volunteers as multiple doses and different dosing regimens over a period of 14 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Cohorts will be dosed sequentially in an ascending fashion with approximately 14 days between starting dose at each dose level.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Day 1 - Day 23 +/- 2 days</time_frame>
    <description>Number and Severity of Treatment Emergent Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <description>Area under PK curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax ss</measure>
    <time_frame>Day 14</time_frame>
    <description>Maximum steady-state plasma drug concentration during a dosage interval (Cmax ss)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Fibrosis</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Cohort A: 1200 mg PBI-4050</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: 1600 mg PBI-4050</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: 2000 mg PBI-4050</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D: 2400 mg PBI-4050</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E: 2400 mg PBI-4050</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F (Supplemental): 2400 mg PBI-4050</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBI-4050/ Placebo</intervention_name>
    <description>Participants receive either 800mg PBI-4050 capsules or placebo, twice a day for 14 days</description>
    <arm_group_label>Cohort B: 1600 mg PBI-4050</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBI-4050/ Placebo</intervention_name>
    <description>Participants receive either 1200mg PBI-4050 capsules or placebo, once a day for 14 days</description>
    <arm_group_label>Cohort A: 1200 mg PBI-4050</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBI-4050/ Placebo</intervention_name>
    <description>Participants receive either 1000 mg PBI-4050 capsules or placebo, twice a day for 14 days</description>
    <arm_group_label>Cohort C: 2000 mg PBI-4050</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBI-4050/ Placebo</intervention_name>
    <description>Participants receive either 1200 mg PBI-4050 capsules or placebo, twice a day for 14 days</description>
    <arm_group_label>Cohort D: 2400 mg PBI-4050</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBI-4050/ Placebo</intervention_name>
    <description>Participants receive either 800 mg PBI-4050 capsules or placebo, three times a day for 14 days</description>
    <arm_group_label>Cohort E: 2400 mg PBI-4050</arm_group_label>
    <arm_group_label>Cohort F (Supplemental): 2400 mg PBI-4050</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or female of non-childbearing potential, between ≥18 years and ≤65 years&#xD;
             of age, inclusive, at screening.&#xD;
&#xD;
          2. Female subject of non-childbearing potential. For the purposes of this study, this is&#xD;
             defined as the subject being amenorrhoeic for at least 12 consecutive months prior to&#xD;
             study drug administration or at least 6 months post-surgical sterilisation (including&#xD;
             bilateral fallopian tube ligation or bilateral oophorectomy with or without&#xD;
             hysterectomy).&#xD;
&#xD;
          3. Female subject with a negative pregnancy test at screening and admission.&#xD;
&#xD;
          4. Male subject (and partner of childbearing potential) willing to use a highly effective&#xD;
             method of contraception or 2 effective methods of contraception, if applicable (unless&#xD;
             anatomically sterile or where abstaining from sexual intercourse is in line with the&#xD;
             preferred and usual lifestyle of the subject) from first dose until 3 months after&#xD;
             last dose of the investigation medicinal product (IMP).&#xD;
&#xD;
          5. Male subjects (including men who have had vasectomies) with a pregnant partner must&#xD;
             agree to use a condom from first dose until at least 3 months (90 days) after last&#xD;
             dose of IMP.&#xD;
&#xD;
          6. Male subjects must be willing to not donate sperm until 3 months (90 days) following&#xD;
             last dose of IMP.&#xD;
&#xD;
          7. Subject with a body mass index (BMI) of &gt;18.5 and &lt;30 kg/m2 and body weight ≥50.0 kg&#xD;
             for males and ≥45.0 kg for females (BMI = body weight (kg) / [height (m)]2), at&#xD;
             screening.&#xD;
&#xD;
          8. Healthy as defined by:&#xD;
&#xD;
               1. Absence of clinically significant illness and surgery within 4 weeks prior to&#xD;
                  dosing. Subjects vomiting within 24 hours (h) pre-dose will be carefully&#xD;
                  evaluated for upcoming illness/disease. Inclusion pre-dosing is at the discretion&#xD;
                  of the PI.&#xD;
&#xD;
               2. Absence of clinically significant history of neurological, endocrinal,&#xD;
                  cardiovascular, pulmonary, haematological, immunologic, psychiatric,&#xD;
                  gastrointestinal, renal, hepatic and metabolic disease.&#xD;
&#xD;
          9. Continuous non-smoker who has not used tobacco or nicotine-containing products for at&#xD;
             least 3 months prior to Screening and throughout the study, or users of cigarette&#xD;
             replacements (i.e., e-cigarettes, nicotine patches or gums).&#xD;
&#xD;
         10. No clinically significant history of previous allergy / sensitivity to PBI-4050 or any&#xD;
             of the excipients contained within the IMP(s).&#xD;
&#xD;
         11. No clinically significant abnormal test results for serum biochemistry, haematology,&#xD;
             coagulation, and/or urine analyses within 28 days before the first dose administration&#xD;
             of the IMP.&#xD;
&#xD;
         12. Subject with a negative urinary drugs of abuse (DOA) screen (including cotinine) and&#xD;
             alcohol breath test results, determined within 28 days before the first dose&#xD;
             administration of the IMP (N.B.: A positive alcohol and/or cotinine test result may be&#xD;
             repeated at the Investigator's discretion).&#xD;
&#xD;
         13. Subject with negative human immunodeficiency virus (HIV), hepatitis B surface antigen&#xD;
             (HBsAg) and hepatitis C virus antibody (HCV Ab) test results at screening.&#xD;
&#xD;
         14. Subject must be available to complete the study (including all follow up visits).&#xD;
&#xD;
         15. Subject must satisfy an Investigator about his/her fitness to participate in the&#xD;
             study.&#xD;
&#xD;
         16. Subject must provide written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A clinically significant abnormality or abnormal laboratory test results found during&#xD;
             medical screening or a positive test for hepatitis B surface antigen (HBsAg),&#xD;
             hepatitis C virus (HCV), or human immunodeficiency virus (HIV) found during medical&#xD;
             screening.&#xD;
&#xD;
          2. Evidence of clinically significant hepatic or renal impairment including alanine&#xD;
             aminotransferase (ALT) and aspartate aminotransferase (AST) above 1.2 x the upper&#xD;
             limit of normal (ULN), direct bilirubin above 1.2 x ULN (total bilirubin accepted up&#xD;
             to 2 x ULN if direct bilirubin is within normal limits), or creatinine is above ULN.&#xD;
&#xD;
          3. An estimated creatinine clearance as assessed by the Cockroft-Gault equation &lt;60&#xD;
             mL/min at screening or admission.&#xD;
&#xD;
          4. Positive urine drug screen (including cotinine) or alcohol breath test at Screening or&#xD;
             admission.&#xD;
&#xD;
          5. History of significant allergic reactions (e.g. anaphylactic reaction and angioedema)&#xD;
             to any drug.&#xD;
&#xD;
          6. Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days&#xD;
             prior to the first study drug administration.&#xD;
&#xD;
          7. Female subject with a positive pregnancy test at screening or admission.&#xD;
&#xD;
          8. Clinically significant electrocardiogram (ECG) abnormalities at screening or&#xD;
             admission, including PR &gt; 220ms QTcF &gt; 450ms.&#xD;
&#xD;
          9. Supine / Semi-supine systolic blood pressure lower than 90 or over 140 mmHg, diastolic&#xD;
             blood pressure lower than 50 or over 90 mmHg at screening.&#xD;
&#xD;
         10. Heart rate less than 40 or over 100 bpm at screening or admission.&#xD;
&#xD;
         11. A clinically significant history of drug or alcohol abuse [defined as the consumption&#xD;
             of more than 14 units for male and female subjects) of alcohol a week], including use&#xD;
             of soft drugs (such as marijuana) or hard drugs (such as cocaine, phencyclidine [PCP],&#xD;
             crack, opioid derivatives including heroin and amphetamine derivatives) within the&#xD;
             past year.&#xD;
&#xD;
         12. Participation in a New Chemical Entity (NCE) clinical study within the previous 3&#xD;
             months or a marketed drug clinical study within the 30 days before the first dose of&#xD;
             IMP, or administration of a biological product in the context of a clinical research&#xD;
             study within the 90 days before the first dose of IMP or concomitant participation in&#xD;
             an investigational study involving no drug or device administration. (Washout period&#xD;
             between studies is defined as the period of time elapsed between the last dose of the&#xD;
             previous study and the first dose of the next study).&#xD;
&#xD;
         13. Use of medication other than topical products without significant systemic absorption,&#xD;
             unless in the opinion of the Investigator and Sponsor's Responsible Physician the&#xD;
             medication will not interfere with the study procedures or compromise subject safety:&#xD;
&#xD;
               1. Prescription medication within 14 days prior to dosing;&#xD;
&#xD;
               2. Non-prescription medication including vitamins, herbal and dietary supplements&#xD;
                  within 7 days or 5 half-lives (whichever is longer), and ibuprofen within 48 h&#xD;
                  prior to the first dose of IMP,&#xD;
&#xD;
               3. A depot injection or an implant of any drug within 3 months before the first dose&#xD;
                  of IMP.&#xD;
&#xD;
         14. Donation of 450 mL or more blood within the 3 months before the first dose of IMP.&#xD;
&#xD;
         15. Donation of plasma within 7 days prior to dosing.&#xD;
&#xD;
         16. Receipt of blood products within 2 months prior to admission.&#xD;
&#xD;
         17. Haemoglobin &lt;130 g/L (males) and &lt;115 g/L (females) and haematocrit &lt;0.36 L/L (males)&#xD;
             and &lt;0.32 L/L (females) at screening or admission.&#xD;
&#xD;
         18. Breast feeding or lactating female subject.&#xD;
&#xD;
         19. A clinically significant history of gastrointestinal disorder likely to influence IMP&#xD;
             absorption.&#xD;
&#xD;
         20. Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or&#xD;
             metabolic dysfunction.&#xD;
&#xD;
         21. Inability to communicate well with the Investigators (i.e., language problem, poor&#xD;
             mental development or impaired cerebral function).&#xD;
&#xD;
         22. Subjects with any special food restrictions that would hinder ability to consume the&#xD;
             high fat breakfast provided during the study; e.g. vegetarian, lactose intolerance,&#xD;
             vegan, low-fat, low sodium, and/or restrictions for medical, religious, social or&#xD;
             cultural reasons, etc).&#xD;
&#xD;
         23. Any reason which, in the opinion of the PI, would prevent the subject from&#xD;
             participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Catherine Simcock</last_name>
    <phone>+44 (0) 1223 433870</phone>
    <email>c.simcock@liminalbiosciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance CRU, Ltd.</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Firas Almazedi, MBChB, MSc, CPI, DipPharmMed</last_name>
      <phone>01133013642</phone>
      <email>firas.almazedi@covance.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

